Guardant Health PE Ratio 2017-2022 | GH
Current and historical p/e ratio for Guardant Health (GH) from 2017 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Guardant Health PE ratio as of February 03, 2023 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Guardant Health PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-02-03 |
31.94 |
|
0.00 |
| 2022-09-30 |
53.83 |
$-5.93 |
0.00 |
| 2022-06-30 |
40.34 |
$-5.41 |
0.00 |
| 2022-03-31 |
66.24 |
$-4.12 |
0.00 |
| 2021-12-31 |
100.02 |
$-4.00 |
0.00 |
| 2021-09-30 |
125.01 |
$-4.05 |
0.00 |
| 2021-06-30 |
124.19 |
$-3.77 |
0.00 |
| 2021-03-31 |
152.65 |
$-3.38 |
0.00 |
| 2020-12-31 |
128.88 |
$-2.58 |
0.00 |
| 2020-09-30 |
111.78 |
$-1.91 |
0.00 |
| 2020-06-30 |
81.13 |
$-1.27 |
0.00 |
| 2020-03-31 |
69.60 |
$-0.83 |
0.00 |
| 2019-12-31 |
78.14 |
$-0.84 |
0.00 |
| 2019-09-30 |
63.83 |
$-0.87 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$3.272B |
$0.374B |
|
Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
|
